Search

Displaying results 5701 - 5710 of 10000 in total
  1. Drug

    Vapendavir

    go.drugbank.com/drugs/DB05181
    Investigational

    BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.

  2. Drug

    [Methyltelluro]Acetate

    go.drugbank.com/drugs/DB01918
    Experimental

    [methyltelluro]acetate is a solid. This compound belongs to the organic oxoanionic compounds. These are organic compounds containing an oxoanion. … This medication targets the protein monomeric sarcosine oxidase.

  3. Drug

    Harmaline

    go.drugbank.com/drugs/DB13875
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds, 2-Ring
  4. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    [A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the amyloid plaques found in individuals with AD and is considered to contribute to the pathophysiology … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand

  5. Drug

    Guretolimod

    go.drugbank.com/drugs/DB21487
    Investigational

    Guretolimod is a small molecule drug. The usage of the INN stem '-tolimod' in the name indicates that Guretolimod is a toll-like receptor (TLR) agonist. … Guretolimod is under investigation in clinical trial NCT03416335 (A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile).

  6. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

  7. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. … These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.

    Synonyms: Anti-SARS-CoV-2 REGN-COV2
  8. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells. … SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma.

  9. Drug

    Carbon black

    go.drugbank.com/drugs/DB11980
    Investigational

    Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function. … [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416]

    Synonyms: VEGETABLE CARBON (E 153), D&C black no. 2
  10. Drug

    Ketazocine

    go.drugbank.com/drugs/DB20132
    Experimental

    Ketazocine is a small molecule drug. The usage of the INN stem '-azocine' in the name indicates that Ketazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. … Ketazocine has a monoisotopic molecular weight of 285.17 Da.

    Categories: Heterocyclic Compounds, 1-Ring